Ardelyx, Inc.

    Jurisdiction
    United States
    LEI
    549300F542QR4SXHCY32
    ISIN
    US0396971071 (ARDX)
    Sectors
    1. Healthcare
    2. Biotechnology

    Scores

    InsiderPie Expert Score
    49 / 100
    Even with peer group:
    50 / 100
    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    5 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    4 / 7

    Profile

    Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. Read full profile

    Fundamentals

    Net revenue
    €329.36M
    Gross margin
    85.4%
    EBIT
    -€34.45M
    EBIT margin
    -10.5%
    Net income
    -€48.10M
    Net margin
    -14.6%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    €415.69M +26.2% €6.34M -113.2%
    N/A €108.50M +1,612.0%
    €668.14M €201.38M +85.6%

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Dividends

    No dividend payouts

    Analyst ratings

    No analyst ratings available

    Insider Transactions

    Name Title Transaction Date Shares Price Value
    Williams Laura A Chief Patient Officer -80K $6.12 -$489.60K
    Foster Eric Duane Chief Commercial Officer -15K $5.93 -$90.78K
    GRAMMER ELIZABETH A See Remarks -5.8K $5.93 -$34.64K
    Kelliher Mike Chief Business Officer -5.4K $5.93 -$32.12K
    RAAB MICHAEL President & CEO -46K $5.93 -$270.92K

    Earnings Calls

    Investor transactions

    Name Shares Value Last change Change type
    Peter Brown 1.4M $6.64M +166K Buy

    Earnings Calls

    Latest earnings call: May 2, 2024 (Q1 2024)

    Add to watchlist

    Notifications